Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inhibitor economics.

Jerome Teitel1

  • 1University of Toronto, Toronto, Ontario, Canada. TEITELJ@smh.toronto.on.ca

Seminars in Hematology
|May 13, 2006
PubMed
Summary
This summary is machine-generated.

Caring for hemophilia patients with inhibitors significantly increases treatment costs due to less effective bypassing therapies and expensive immune tolerance induction. These costs can be 2.5 times higher than for patients without inhibitors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deferral of immunosuppression in acquired hemophilia.

Blood advances·2025
Same author

More real-world evidence on the impact of emicizumab.

Research and practice in thrombosis and haemostasis·2025
Same author

Journeying Towards Excellence in the Care of Patients with Haemophilia and Other Inherited Bleeding Disorders From a Developing World: Insights From Tanzania.

Journal of blood medicine·2025
Same author

Antisemitism in Medicine: An International Perspective.

Rambam Maimonides medical journal·2024
Same author

Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.

The New England journal of medicine·2024
Same author

Health-care workers can take the lead in ending the war in Gaza.

Lancet (London, England)·2024
Same journal

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026
Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026
Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026
Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026
Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
See all related articles

Area of Science:

  • Hematology
  • Pharmacoeconomics

Background:

  • Hemophilia treatment primarily involves clotting factor concentrates (CFC).
  • High-titer inhibitors render CFC ineffective, necessitating bypassing agents.
  • Inhibitors substantially alter treatment costs and complexity.

Purpose of the Study:

  • To analyze the economic impact of high-titer inhibitors in hemophilia treatment.
  • To compare direct treatment costs between inhibitor and non-inhibitor hemophilia patients.

Main Methods:

  • Review of direct cost data for hemophilia patient treatment.
  • Comparison of costs associated with clotting factor concentrates versus bypassing agents.
  • Analysis of costs for immune tolerance induction protocols.

Main Results:

Related Experiment Videos

  • Bypassing agents are less predictable and more expensive per unit than CFC.
  • Treatment costs for hemophilia patients with inhibitors are significantly higher.
  • Immune tolerance induction protocols add substantial costs due to prolonged, frequent CFC dosing.
  • Estimated cost for inhibitor patients can be 2.5 times higher than for non-inhibitor patients.
  • Outlier patients with high treatment needs can disproportionately increase overall costs.

Conclusions:

  • High-titer inhibitors represent a major cost driver in hemophilia care.
  • Treatment strategies for inhibitor patients require careful economic consideration.
  • Cost assessments for hemophilia patients with inhibitors are less predictable due to outlier effects.